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CM: conditioned media  
MCM: MDA-MB-231 conditioned media 
LCM: LoVo conditioned media 
HMW: high molecular weight 
LMW: low molecular weight 
TL: tumor cell lysate 
MTL: MDA-MB 231 tumor cell lysate 
LTL: LoVo tumor cell lysate 
TTL: tumor tissue lysate 
NATL: normal tissue adjacent to the tumor lysate 
Mo: monocytes 
MØ: macrophages 
TSG-6: tumor necrosis factor (TNF)-stimulated gene 6 
PBMCs: peripheral blood mononuclear cells 
ECs: endothelial cells 
NRQ: normalized relative quantities 
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Abstract 
Hyaluronan is a glycosaminoglycan normally present in the extracellular matrix in most 
tissues. Hyaluronan is a crucial player in many processes associated with cancer, such as 
angiogenesis, invasion and metastasis. However, little has been reported regarding the action 
of hyaluronan on monocytes/macrophages in tumor angiogenesis and its consequences on 
tumor development. In the present study, we investigated the effects of hyaluronan of 
different sizes on human monocytes/macrophages angiogenic behavior in colorectal and 
breast carcinoma. In vitro, treatment of monocytes/macrophages with lysates and conditioned 
media from a breast, but not from colorectal, carcinoma cell line plus high molecular weight 
hyaluronan induced: i) an increased expression of angiogenic factors VEGF, IL-8, FGF-2 and 
MMP-2, ii) increased endothelial cell migration and iii) a differential expression of 
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derived from breast cancer patients treated with tumor lysates. Besides, macrophages primed 
with high molecular weight hyaluronan and inoculated in human breast cancer xenograft 
tumor increased blood vessel formation and diminished TSG-6 levels. In contrast, the effects 
triggered by high molecular weight hyaluronan on monocytes/macrophages in breast cancer 
context were not observed in the context of colorectal carcinoma. Taken together, these 
results indicate that the effect of high molecular weight hyaluronan as an inductor of the 
angiogenic behavior of macrophages in breast tumor context is in part consequence of the 
presence of TSG-6. 
 
Introduction 
Hyaluronan (HA), an anionic non-sulfated glycosaminoglycan, is a main component of the 
extracellular matrix in tissues. HA functions are well known to be size-dependent. At 
homeostasis, high-molecular weight HA (HMW HA: 1500-1800 kDa) is predominant and has 
hydrodynamic properties, whereas low-molecular weight HA (LMW HA: 100-300 kDa) is 
present mainly during inflammation [1]. It is well known that HA binds several cell surface 
receptors such as CD44, TLR4 and RHAMM and its size can influence the receptor 
activation and downstream signaling [2]. Even more, tumor necrosis factor (TNF)-stimulated 
gene 6 (TSG-6) is a hyaluronan binding protein. TSG-6 has a crucial role in the formation of 
HA crosslinking with other matrix components, such as the serine protease inhibitor inter-α-
inhibitor (IαI) heavy chains (HCs) which allows stabilization and structural integrity of the 
extracellular matrix [3-5]. 
 
On the other hand, HA is a crucial player in many processes associated with cancer [6] and 
has been detected in tissues [6], as well as serum, in multiple types of cancer [7]. Particularly, 
HA was detected in serum from breast cancer patients [8, 9]. In several tumors, LMW HA 
promotes spreading by stimulating angiogenesis and creating a microvascular network [10]. 
However, we have previously demonstrated that in colorectal carcinoma exogenous LMW 
but not HMW HA, significantly reduced tumor growth in vitro and in vivo, in part by its 
immunostimulatory action [11]. Although in breast carcinoma, LMW HA and not HMW HA 
may contribute to tumor progression [12]. These controversial results might be due to not 
considering the impact on tumor-associated cells, such as monocytes/macrophages and 
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Monocytes (Mo) are circulating innate immune cells. Some monocytes migrate into tissues or 
to the sites of damage or infection where they subsequently develop into different type of  
monocyte-derived macrophages (MØ). Cells of this lineage are jointly described to as 
mononuclear phagocytes or monocytes/macrophages (Mo/MØ) [13]. These cells participate 
in many states of physiological and pathological processes, in addition to their role in the 
immune response [14]. MØ are critical modulators of the tumor microenvironment, although 
its behavior differs considerably among tumors. They are classically known as tumor-
associated macrophage (TAM) and considered an M2 type or regulatory MØ, which are  able 
to promote angiogenesis [15]. Mo/MØ are able to bind HA which induces intracellular 
signals [16, 17], however, the role that different sized HA plays on MØ behavior in the 
presence of tumor factors is not well known, defining their anti or pro-tumor effect. 
Moreover, TSG-6 is not in general a constitutively expressed protein in normal adult tissues 
and during inflammation its expression is upregulated. This HA binding protein is produced 
by activated MØ modulating inflammation process as a consequence of tissues injury [5, 18, 
19]. However, its mechanism of action and its role in Mo/MØ behavior are not fully 
understood in cancer. Consequently, the aim of our work was to evaluate HA (LMW and 
HMW) effect on human Mo/MØ angiogenic behavior in two different tumor 
microenvironments, colorectal and breast. It is well known that tumor necrosis is related to a 
more angiogenic and inflammatory microenvironment in various types of cancer [20, 21], 
among them breast cancer [22]. That is why we evaluated Mo/MØ behavior exposed to 
factors from tumor cell lysates or cell supernatants. On the other hand, we analyzed the role 
of TSG-6 as a modulator of HA function within these tumor microenvironments. 
 
Results 
HA fails to modulate phenotypic markers of Mo/MØ in tumor microenvironments. 
To characterize peripheral blood mononuclear cells (PBMCs) derived Mo/MØ by expression 
of cell surface antigens, we evaluated by flow cytometry different cell surface markers: 
CD14, HLA, CD80 and CD206. Monocytes were gated by CD14 positive expression and the 
co-expression of the markers was analyzed to immune characterize Mo/MØ. On average, 
81% of the cells in culture expressed this marker, indicating a higher homogeneity of the 
culture and their monocytic lineage (Fig.1). Besides, no differences were found between 
treatments. HA (HMW or LMW) and factors from tumor cell lysates (TL) were not able to 










This article is protected by copyright. All rights reserved. 
results were observed during treatment of macrophages exposed to conditioned media (CM) 
(Fig. 1B). TL and CM concentration does not affect Mo/MØ viability (Fig. 2). Therefore, HA 
plus TL or CM were not able to modulate the Mo/MØ surface markers. Since our aim was to 
study the modulation of HA on Mo/MØ angiogenic function in tumor context, we analyzed 
the expression of pro-angiogenic molecules: VEGF, FGF-2, IL-8 and MMPs. 
 
HMW HA increased VEGF production in Mo/MØ in breast but not in colorectal carcinoma 
microenvironment. 
As it was previously mentioned, TAMs induce tumor vascularization by releasing several 
factors, including VEGF which is the main angiogenic factor. Thus, VEGF expression was 
analyzed to evaluate the effect of HA (LMW and HMW) on Mo/MØ pulsed with TL from 
breast cancer cell line MDA-MB-231 (MTL) or colorectal carcinoma cell line LoVo (LTL). 
Mo/MØ treated with MTL plus HMW HA significantly increased VEGF levels (NRQ: 3,769 
± 0,9416) when compared to MTL without HA (NRQ: 0,3000 ± 0,1732) or MTL plus LMW 
HA (NRQ: 0,3587 ± 0,2071) (Fig. 3 A). No differences were observed between treatments 
with LTL (Fig. 3 A). In order to evaluate VEGF expression modulated by CM we performed 
a RT-qPCR. Mo/MØ were treated with CM derived from MDA-MB-231 (MCM) or LoVo 
(LCM). VEGF levels increased when Mo/MØ were treated with MCM plus HMW HA 
(NRQ: 3.216 ± 0.06561) in comparison with MCM treatment without HA (NRQ: 0.1100 ± 
0.0110) and plus LMW HA (NRQ: 0.0 ± 0.0) (Fig. 3 B). Mo/MØ treated with LCM plus HA 
(LMW or HMW) showed no differences in VEGF expression levels. Taken together these 
results indicate that HMW HA is able to increase VEGF levels in Mo/MØ in a breast 
carcinoma context.  
 
HMW HA increased the expression of IL-8 and FGF-2 in Mo/MØ in breast but not in 
colorectal carcinoma microenvironment 
Mo/MØ express and secrete other important angiogenic factors, like IL-8 and FGF-2. 
Consequently, we evaluated the mRNA expression levels of IL-8 and FGF-2 of Mo/MØ 
pulsed with TL or CM with or without HA. In concordance with VEGF synthesis levels, 
Mo/MØ incubated with MTL plus HMW HA increased IL-8 expression levels (NRQ: 5.761 
± 1.461) when compared to the treatments with MTL without HA (NRQ: 2.630 ± 0.5698) or 
MTL plus LMW HA (NRQ: 1.756 ± 0.1945) (Fig. 3 C). When we analyzed IL-8 levels from 
Mo/MØ treated with CM, we observed a significant increase of IL-8 with the treatment with 
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treated with MTL plus HMW HA (NRQ: 2.972 ± 0.8020) showed an increased tendency 
when compared to MTL without HA (NRQ: 2.461 ± 0.5345) and a significant increase 
comparing to BC (NRQ: 0.3447 ± 0.09539) (Fig. 3 E). Similarly, Mo/MØ treated with HMW 
HA plus MCM increased FGF-2 expression levels (NRQ: 4.150 ± 0.2656) comparing to 
MCM (NRQ: 2.280 ± 0.3600) and MCM plus LMW HA (NRQ: 0.9050 ± 0.3650) (Fig. 3 F). 
Mo/MØ treated with LTL or LCM plus HA (LMW or HMW) showed no differences in the 
mRNA expression levels of IL-8 and FGF-2 (Fig. 3 C-F).  
 
HMW HA treatment modulated MMPs expression levels and activity in Mo/MØ in a breast 
but not in colorectal carcinoma microenvironment 
In tumor context, Mo/MØ upregulate MMP-2 and MMP-9 production and their proteolytic 
activity triggers the degradation of the extracellular matrix and the bioavailability of 
angiogenic factors [23]. Thus, we analyzed MMPs activity by gelatin zymography as another 
angiogenic mechanism regulated by HA. MMP-9 activity showed no difference between HA 
treatments with TL and CM (Fig. 4 A and E) in Mo/MØ. However, the treatment with MTL 
plus HMW HA increased MMP-2 activity (NRQ: 5.685 ± 0.2162) in these cells (Fig. 4 C) 
compared to BC. The HA action was not only restricted to HMW HA, the treatment with 
MTL plus LMW HA also increased its activity (NRQ: 6.278 ± 0.5816) (Fig. 4 C). MMP-2 
showed similar activity in Mo/MØ PBMCs pulsed with LTL both treatments and controls 
(Fig. 4 C).  In addition, to corroborate these results we analyzed mRNA levels of MMP-9 and 
MMP-2. As expected, MMP-9 expression levels showed no differences during the treatments 
(Fig. 4 B). MMP-2 mRNA levels significantly increased with MTL plus HMW HA treatment 
(NRQ: 5.685 ± 0.2162) with respect to MTL (NRQ: 3.343 ± 1.220) (Fig. 4 D). MCM or 
LCM treatments of Mo/MØ did not modulate MMPs activity or their expression levels (Fig. 
4 F and H). 
 
Higher in vitro migration of ECs towards Mo/MØ supernatants when treated with HMW HA 
in a breast but not in colorectal carcinoma microenvironment 
We decided to test the migration of ECs in vitro, as a way of evaluating the functional 
modulation of these cells involved in the vessel formation. As expected, significantly higher 
migration of ECs was observed towards the supernatants of Mo/MØ treated with MTL plus 
HMW HA (index cell migration: 6.830 ± 1.465) when compared to MTL without HA (index 
cell migration: 3.523 ± 0.5100) and MTL plus LMW HA (index cell migration: 1.380 ± 
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migration levels of ECs (Fig. 5). Moreover, differential migration was observed in ECs 
towards Mo/MØ supernatants derived in the presence of MTL (index cell migration: 3.523 ± 
0.5100) when compared with LTL (index cell migration: 0.7459 ± 0.1051). We were not able 
to perform this experiment with tumor cells CM since MCM as well as LCM are 
chemoattractants of ECs per se and did not allow us to evaluate differences among the 
treatments.  
  
Mo/MØ treated with HMW HA modulated HA receptors expression levels in a breast 
carcinoma microenvironment 
HA induces cell signaling through several receptors such as CD44, TLR-4 and RHAMM. 
Since these receptors are involved in HA responses in Mo/MØ cells, we examined the effect 
of TL or CM with or without HA addition on their mRNA expression levels. The treatment 
with HWM HA induces an increase of CD44 expression levels (NRQ: 1.676 ± 0.3466) with 
respect to BC (NRQ: 1.107 ± 0.1700), but has no significant effect on TLR-4 or RHAMM 
expression levels (Fig. 6 A, C and E). Besides, MTL plus HMW HA significant decreased 
expression levels CD44 (NRQ: 0.5866 ± 0.02388) and TLR4 (NRQ: 0.4602 ± 0.1234), in 
comparison to the treatment of MTL without HA (NRQ: 2.043 ± 0.4256), without modulating 
RHAMM expression levels (Fig. 6 A, C and E). In contrast, no differences were observed 
among the LTL treatments (Fig. 6 A, C and E). We also evaluated the behavior of Mo/MØ 
cells exposed to CM from tumor living cells. These CM did not affect CD44, TLR-4 and 
RHAMM expression levels (Fig. 6 B, D, F). However, MCM plus HMW HA significantly 
decreased TLR-4 expression levels (NRQ: 0.7250 ± 0.01500) in comparison to MCM without 
HA treatment (NRQ: 1.635 ± 0.03500) (Fig. 6 D). CD44 and RHAMM levels showed no 
difference between MCM treatments (Fig. 6 F). As for LCM treatments, no differences were 
observed among them in the expression levels of the receptors analyzed (Fig. 6 B, D and F).   
 
Mo/MØ preincubated with HMW HA increased the tumor vasculature in the breast cancer 
model 
We tested whether the in vitro angiogenic effects could be observed in an in vivo model. For 
this purpose, nude mice were injected with MDA-MB-231 or Lovo cells and nine days later 
animals with similar tumor volume were inoculated with Mo/MØ preincubated with HMW or 
LMW HA. Tumor volume was measured weekly and we found no differences in tumor 
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with: i) H&E to rule out changes in tumor histology or ii) GSL-1 to analyze ECs forming 
blood vessel. 
 
We observed that Mo/MØ preincubated with HMW induced a significant increment of the 
tumor vasculature in the MDA-MB-231 model detected by immunofluorescence intensity 
(AU) of GSL-1-FITC (AU: 1.759 ± 0.1173) compare to Mo/MØ without treatment (AU: 
1.158 ± 0.1193) and pulsed with LMW HA (AU: 1.017 ± 0.07250) (Fig. 7 A). Besides, the 
tumor vasculature decreased in those animals inoculated with Mo/MØ previously treated with 
LMW HA in comparison with tumor control (AU: 1.602 ± 0.1307) (Fig. 7 A). However, in 
LoVo model, we observed no difference in the vasculature after all treatments (Fig. 7 B). 
Tissues section for each model and treatments presented similar tumor structure without 
necrosis areas. In conclusion, in vivo data confirm and is in concordance with the in vitro 
results. 
 
TSG-6 production by Mo/MØ is deregulated with HMW HA in a breast carcinoma 
microenvironment 
Taking into account the results presented above we could indicate that there is a factor whose 
expression in Mo/MØ is triggered by HMW HA in breast carcinoma context but not in 
colorectal. Therefore we decided to evaluate gene and protein expression levels of TSG-6, a 
hyaluronan-binding protein that modulates its structure and function in inflammatory or 
tissue injury process [5, 24]. Firstly, GEO2R was applied to screen TSG-6 expressed mRNAs 
levels in macrophages. TSG-6 was screened in two mice datasets: breast (GSE18404) and in 
colorectal (GSE67953) carcinoma; TSG-6 was expressed in both datasets but no differences 
were found between TAMs and spleen macrophages (Fig. 8). We observed that TSG-6 
mRNA expression levels were not modulated significantly in Mo/MØ treated with LMW or 
HMW HA. However, we found different TSG-6 expression levels when Mo/MØ were pulsed 
with MTL (NRQ: 5.860 ± 2.711) compared to BC (NRQ: 0.3615 ± 0.1206) and LTL (NRQ: 
1.233 ± 0.4856) (Fig. 9 A). Besides, TSG-6 mRNA levels decreased in Mo/MØ treated with 
MTL plus HMW HA (NRQ: 0.4540 ± 0.1535) in comparison to MTL without HA (NRQ: 
NRQ: 5.860 ± 2.711). Whereas, Mo/MØ pulsed with LTL, with or without HA, showed no 
differences in TSG-6 mRNA levels (Fig. 9 A). In the case of CM treatments, MCM plus 
HMW HA significantly increased TSG-6 mRNA levels (NRQ: 18.35 ± 4.835) when 
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In addition, we analyzed TSG-6 protein expression through Western blot in Mo/MØ 
supernatants and we detected two species: i) ∼35 kDa corresponding to free TSG-6 and ii) 
∼120 kDa corresponding to the complex generated by the heavy chain (HC) of IαI and TSG-
6, as have been documented by other authors [25]. We found that in Mo/MØ supernatants 
free TSG-6 was increased with MTL treatment (AU: 24.73 ± 3.472) or LTL treatment (AU: 
19.78 ± 2.301) with respect to BC (AU: 2.773 ± 1.337) (Fig. 9 B). MTL plus HMW HA 
diminished the 120 kDa species, when compared to MTL (AU: 10.69 ± 1.297). LTL plus 
HMW HA (10.69 ± 1.297 AU) diminished the 120 kDa species, when compared LTL (11.56 
± 1.054 AU) without HA treatment (Fig. 9 B).  
 
We also performed TSG-6 western blot from Mo/MØ supernatants treated with MCM or 
LCM (Fig. 9 D). MCM plus HMW HA increased ∼35 kDa species corresponding to free 
TSG-6 (AU: 9.755 ± 0.07500) with respect to MCM (AU: 4.675 ± 0.3850) and BC (AU: 
2.773 ± 1.337) (Fig. 9 D). However, the ∼120 kDa species, corresponding to TSG-6·HC, 
significantly decreased with MCM plus HMW HA (AU: 5.347 ± 1.509) when compared to 
MCM without HA (AU: 10.78 ± 2.289). This species corresponding TSG-6·HC were not 
detected in the supernatants of Mo/MØ treated with LCM with or without HA (Fig. 9 D right 
panel).  
  
Mo/MØ preincubated with HMW HA decreased TSG-6 levels in breast cancer model 
In order to evaluate the intrinsic effects of these molecules in the tumor stroma, tumor 
sections of xenograft models were stained with TSG-6 and HA by immunofluorescence. In 
the MDA-MB-231 model, mice inoculated with Mo/MØ without treatment (AU: 3.201 ± 
0.3712) increased TSG-6 levels respect to control mice (without inoculation of Mo/MØ) 
(AU: 1.624 ± 0.1989) (Fig. 10 A). Besides, mice inoculated with Mo/MØ preincubated with 
HMW HA, which presented a significant increment of the tumor vasculature, decreased TSG-
6 immunofluorescence intensity (AU: 1.820 ± 0.4308) when compared to mice inoculated 
with Mo/MØ without treatment (AU: 3.201 ± 0.3712) (Fig. 10 A). In contrast, TSG-6 levels 
in the LoVo model presented no differences among treatments (Fig. 10 B). These TSG-6 
results from the in vivo model are in concordance with the in vitro results obtained for TSG-6 
mRNA levels (Fig. 9 A). When we analyzed total endogenous HA levels, we found no 
significant differences in the MDA-MB-231 model. Contrary, tumor sections derived from 
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significant increment in total HA (Fig. 10 B). Thus, despite similar or dissimilar 
accumulation of HA in the tumor is the differential expression of TSG-6 that might affect HA 
action in Mo/MØ within both tumor models, which also affect their angiogenic behavior.   
 
TSG-6 levels were deregulated when Mo/MØ derived from cancer patients were treated with 
HMW HA and tumor tissues lysates 
To further evaluate HA effect on human Mo/MØ angiogenic behavior we used Mo/MØ 
derived from cancer patients (breast and colorectal) and we prepared from each patient 
lysates from tumor tissue (TTL) and from normal tissue adjacent to the tumor (NATL).  In 
Mo/MØ samples derived from breast cancer patients (ER-positive), free TSG-6 protein levels 
(∼35 kDa species) increased with TTL treatment plus HMW HA (AU: 19.94 ± 0.7000) 
respect to TTL without HA (AU: 7.485 ± 2.045) (Fig. 11 A, right panel). Free TSG-6 levels 
did not show significant differences among NATL treatments (Fig. 11 B, right panel). As for, 
TSG-6·HC (∼120 kDa species) it showed a decrease when Mo/MØ were treated with breast 
TTL plus HMW HA (AU: 6.215 ± 1.225) in comparison to TTL (AU: 16.34 ± 2.095) (Fig. 11 
A, left panel), but among NATL treatments we did not observe significant differences (Fig. 
11 B, left panel). Mo/MØ samples derived from colorectal carcinoma showed no significant 
differences between TTL or NATL treatments.  
  
Discussion 
Macrophages derived from monocytes, exhibit a diversity cell behavior, beyond its 
immunological role. These cells secrete crucial factors for growth and remodeling of the 
microvasculature during angiogenesis. Despite vast investigations of Mo/MØ response to 
tumor cells and inductors of angiogenesis, few studies are focused on evaluating their 
behavior considering the extracellular matrix interaction. This issue is an important point of 
study to develop novel cancer therapies that target angiogenesis and simultaneously 
immunosuppression. For example, it has been demonstrated that disruption of angiogenesis 
substantially enhances the efficacy of immune-based cancer therapies [26].    
 
As it was previously mentioned, HA is one of the extracellular matrix components that can 
modify the behavior of both tumor and immune cells types [1]. HA interacts with Mo/MØ 
inducing their migration, the release of chemokines, cytokines, growth factors and expression 
of MMPs [27]. However, it has been observed that HA released by tumor cells selectively 
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showed that HA derived from breast cancer induces MØ to acquire an immunosuppressive or 
M2-like phenotype [30]. It is well established that HA size is critical for its function. Thus, 
we used LMW HA and HMW HA of defined size in our experiments. We observed that HA, 
both as LMW or HMW, in the presence of tumor factors, either from tumor lysates or 
conditioned media from breast (MTL) or colorectal (LTL) cells, did not affect surface 
markers that define the MØ phenotype [31]. Besides, it is important to consider that Mo/MØ 
behavior and function is not only defined by cell surface markers, and a better 
characterization may also be possible in vivo based on the paracrine factors that they secrete.  
 
To evaluate Mo/MØ as an inductor of angiogenesis under HA treatments in a tumor context, 
we analyzed the expression of biosynthesis of VEGF, the main angiogenic factors (Fig. 3 A 
and B). We evaluated Mo/MØ behavior between the different tumor types and exposing them 
to tumor cells lysates (TL) or soluble factors from tumor cells conditioned media cells (CM).  
These cells need to be stimulated to produce VEGF and HA by itself was not able to induce 
this expression. Even more, HMW HA but only in the presence of breast carcinoma antigens 
(MTL or MCM) increased significantly VEGF mRNA levels (Fig. 3 A and B). Similar results 
were observed when we evaluated other pro-angiogenic molecules like IL-8 and FGF-2 (Fig. 
1 C-F)[32]. Thus, it is possible to hypostatize that there are different factors in the tumor 
lysates or conditioned media from breast cancer cells, but not in colorectal cancer cells, that 
could be modulating the function of HWM HA on Mo/MØ. Besides, we found a significant 
increase in MMP-2 gelatinolytic activity when Mo/MØ were treated with HA (LMW or 
HMW) in the presence of MTL (Fig. 4 C). Although mRNA MMP-2 levels increased only 
during the treatment with MTL plus HMW HA (Fig. 4 D). It was documented that MMP-2 
cleaves collagen type IV and it is associated with ECs migration, affecting their capacity to 
generate new vessel [33]. Besides, it was previously demonstrated that HA-CD44 interaction 
allows the activation of MMP-2 [34]. Thus, factors that modulate HA function might be 
directly connected with the MMP-2 activity, since we observed a modulation with MTL but 
not with LTL treatment.  To further study the biological function of angiogenic factors 
released with the different treatments, we analyzed the migration capability of ECs towards 
the Mo/MØ supernatants. A higher migration was observed with MTL and even more with 
MTL plus HMW HA treatment (Fig. 5), suggesting that factors in MTL induce an HA with 
pro-angiogenic action on Mo/MØ. In turn these cells release VEGF, IL-8, FGF-2 and MMP-2 
that stimulate ECs migration. Similar results were observed when we evaluated angiogenesis 










This article is protected by copyright. All rights reserved. 
staining in tumor tissue of MDA-MB-231-bearing mice that were treated with MØ primed 
with HMW HA but no differences were detected in LoVo-bearing mice (Fig. 7). 
 
To study HA receptors that are involved in the Mo/MØ responses, we evaluated CD44, TLR-
4 and RHAMM mRNA expression levels (Fig. 6). It has been shown that CD44 and TLR-4 
are involved in immune deactivation of human Mo/MØ cells [23] Actually, modulation of 
this receptors expression affects their immune phenotype and function within tumor 
microenvironment [1]. We only observed modulation of these receptors in Mo/MØ exposed 
to treatments with antigens from breast cancer cells lines. We observed that HMW HA 
treatment induced a significant downregulation of CD44 and TLR-4 expression in Mo/MØ in 
the presence of MTL, for TLR-4 we also observed a significant decrease with MCM plus 
HMW HA.  Thus, the decrease of HA receptors expression could be associated with 
angiogenesis and involved in HA response in vivo according to the type of tumor 
microenvironment. In light of these results, we carried out subsequent experiments to identify 
the factor/factors that is/are modulating the HA function and in turn Mo/MØ angiogenic 
behavior in both types of cancer. Although HA is not covalently linked to a core protein, it 
can interact with HA-binding proteins or hyaladherins, that in turn modulate HA structure 
and function. TSG-6, is a well-characterized hyaladherin, with an HA-biding site located 
within a domain called “link module” [18, 24]. For example, it has been observed that 
aggregation of HA IαI-induced is dependent on TSG-6 and allows the stabilization of the 
extracellular matrix [24]. Thus, alteration of TSG-6 might affect HA function. We suggest 
that the differences found in Mo/MØ behavior when they were exposed to different sizes of 
HA and different tumor types could be associated with HA-binding proteins that in turn 
modulate HA action. In most cell types, the expression of TSG-6, as immunoregulator 
mediator, is stimulated by cytokines or factors released during inflammation, inflammation-
like or injury processes. It is proposed that TSG-6 controls inflammation response and 
maintains the extracellular matrix homeostasis [18].  
 
For the first time, we detected a reduction in the expression levels of the bands corresponding 
to the complex TSG-6·HC only when Mo/MØ were treated with HA (HMW or LMW) plus 
MTL, LTL or MCM. Markedly, TSG-6·HC protein expression was only modulated in breast 
tumor context. Indicating that specific tumor factors could induce an immunosuppressive and 
angiogenic action of TAMs by modulating TSG-6, and its expression within the tumor is also 
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6·HC complex is indicative of the enzymatic activity of TSG-6. It is well known that TSG-6 
catalyze the transfer of the IαI HC to HA, affecting the activity of this proteinase inhibitor [3, 
4] as well as HA structure, the binding capacity to its receptors and therefore its function 
[24]. 
 
Even more, we used xenograft nude mice models, which does not allow the development of 
adaptive immune response, but innate immune response is still intact and offers a tumor 
milieu to study Mo/MØ function and regulation of angiogenesis. We observed that the 
treatment of Mo/MØ induced an increase of TSG-6 that was significantly reduced during the 
treatment of Mo/MØ preincubated with LMW HA in breast carcinoma model (Fig. 10 A). 
These results are in concordance of in vitro results where TSG-6 mRNA levels decreased in 
Mo/MØ treated with MTL plus HMW HA in comparison to MTL without HA. When HA 
expression was analyzed in tumor tissues, no changes were detected in the breast carcinoma 
model. This indicates that different function of HA is dependent on factors or antigens of the 
tumor microenvironments than the amount of HA present within the tissues. The analysis of 
Mo/MØ treated with tumor or normal adjacent tissue derived from patients with invasive 
breast carcinoma (ER+, stage I or II) or colorectal carcinoma (stage I or II) allowed us to 
extend our results in the context of different types and stages of breast and colorectal 
carcinoma. Mo/MØ cells treated with TTL from breast cancer patients plus HMW HA also 
modulates both species of TSG-6 (HC bonded and free). Besides, no modulations were 
observed from colorectal cancer and normal tissues. Considering our results, we can conclude 
that modulation of TSG-6 activity and expression is differentially modulated according to 
tumor type. However, further studies will be necessary to find the factors present in breast 
carcinoma that are involved in this HA-TSG-6 regulation loop.   
 
As for Mo/MØ treated with colorectal carcinoma antigens, HMW HA did not affect HA 
receptors, TSG-6 nor their angiogenic behavior. Interestingly, the role of macrophages in 
colorectal carcinoma is controversial. Some studies support that TAMs exhibit tumor-
suppressive abilities, whereas others report that these cells contribute to colorectal cancer 
promotion [35]. However, it was shown that high density of tumor-associated MØ correlates 
with poor prognosis in breast carcinoma since this cells were capable of inducing 
angiogenesis, remodeling the tumor extracellular matrix to aid invasion, modeling breast 
cancer cells to evade host immune system and recruiting immunosuppressive leukocytes to 
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Finally, this study showed for the first time that HMW HA, a highly conserved and poorly 
immunogenic molecule, downregulates TSG-6 levels in Mo/MØ modulating their angiogenic 
behavior in breast carcinoma milieu, but not in colorectal carcinoma. Even more, CM 
induced downregulation of TSG-6-HC complex could be essential for in vivo angiogenesis 
because this effect was not observed in LCM. These findings are of great interest, since it 
may provide novel breast cancer targets, especially to increase the success of anti-angiogenic 
agents. 
 
Materials and Methods 
Reagents 
Pharmaceutical endotoxin-free HA recombinant of definite size: HMW 1.5–1.8 x 106 Da and 
LMW 1–3 x 105 Da from CPN spol.s.r.o was kindly supplied by Farmatrade. 
 
Cell lines and human blood 
LoVo (human colorectal adenocarcinoma) provided by Dr. Lucia Policastro (Instituto de 
Nanociencia y Nanotecnología, BA, Argentina) and MDA-MB-231 (breast adenocarcinoma) 
by Roxana Schillaci (IBYME, CABA, Argentina) were maintained with DMEM/F12 
supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml streptomycin and 100 mg/ml 
penicillin and incubated at 37°C in a 5% CO2 humidified atmosphere. HMEC-1 (dermal 
microvascular endothelium) cell line was cultured with DMEM supplemented with 10% FBS, 
2 mM L-glutamine, 100 U/ml streptomycin and 100 mg/ml penicillin and incubated at 37°C 
in a 5% CO2 humidified atmosphere. In all cell cultures, periodic checkups of cell 
morphology were performed, as well as strict control of cell line passages (5 -10th passage) 
and cell line growth rate. In addition, all cell lines were analyzed to discard the presence of 
mycoplasma contamination by PCR assay. 
 
Peripheral blood samples for human monocyte isolation were obtained from voluntary blood 
donors and from cancer patients. Tumor tissue as well as normal tissue adjacent to 
the tumor (NAT) were obtained from cancer patients. Approval was obtained from the 
Institutional Assessment Committee (CIE) – IRB within the Austral University Hospital (CIE 
N° 17-006). Informed consent was obtained from participants in accordance with the 
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Tumor lysates and conditioned media 
Confluent cultures of LoVo or MDA-MB-231 cells were detached with cold PBS, washed 
twice in PBS and resuspended in PBS. Cell suspensions (1,2x10
6
 cells/ml) and conditioned 
media (CM) were frozen at -80°C. The cell suspensions were disrupted by 5 freeze-thaw 
cycles. To remove large debris, tumor lysates (TL) MDA-MB-231 (MTL) or LoVo (LTL) 
were centrifuged at 300 rpm for 10 min.  The supernatant was collected and passed through a 
0.22 mm filter unit. Conditioned media (CM) were collected from supernatants from tumor 
cell lines MDA-MB-231 (MCM) or LoVo (LCM) cultured (1,2x10
6
 cells) for 6 h without 
serum.  The protein concentration was determined by Bradford assay. As for cancer patient’s 
lysates were prepared using the same protocol for tumor lysates previous mechanical 
disintegration of the tissues. Lysates derived from tumor tissue (TTL) and from normal tissue 
adjacent to the tumor (TNAT). The resulting TL or CM were aliquoted and stored at -80°C 
until use.  
 
Isolation of PBMC-derived Mo/MØ 
PBMCs were isolated by the Ficoll-Paque Plus (GE Healthcare) gradient. Cells were plated 
into 12-well plates for 2 h, removing the non-adherent cells. Then, adhered cells were 
subsequently cultured overnight  in complete RPMI 1640 medium [37]. 24 h later, the 
medium of the adherent MØ was replaced with RPMI 1640 (FBS free) and were pulsed with 
either with conditioned media or TL (200 µg/10
6
 cells/ml) with or without LMW HA (20 
µg/ml) or HMW HA (20 µg/ml). After 24 h cells were centrifuged, characterized by flow 
cytometry and used for experiments.  
 
MTS 
Cell viability assay was measured by MTS method (ab197010, Abcam) as described in the 
manufacture protocol. Mo/MØ treated with MTL or LTL (0, 100, 200 and 400 μg/ml) were 
seeded in 96-well plates at a density of 6 × 10
3
 per well and 3 hours before the treatments 
ended the MTS dye was added, and then incubated for 3 hours in the dark. The optical 
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Flow cytometry analyses 
Staining and flow cytometric analyses of PBMCs derived MØ were carried out using 
standard procedures. Briefly, 10
6
 cells were blocked with PBS-1% BSA for 45’ and then 
were stained on ice for 30 min with different conjugated antibodies: anti-CD14; anti-MHC-II 
(G46-6); anti-CD80 (L307.4); and anti-CD206 (all from BD Biosciences). Cells were washed 
thoroughly with PBS-1% BSA and subjected to flow cytometry (FACS CANTO II-BD). Data 
were analyzed using Flow 7.6.2 software. 
 
ELISA assays 
VEGF expression levels were determined by a sandwich ELISA assay (DY293B, R&D 
Systems
TM
) from free-cell conditioned media. The assays were carried out according to the 
instructions provided by the manufacturer.  
 
RT-qPCR 
Total RNA was extracted by Tri Reagent (TR 118, Molecular research center, Inc.). RNA 
quantification was evaluted by spectrophotometry. Then, 2 µg of RNA was reverse 
transcribed with 200U RT M-MLV Reverse Transcriptase (M1701, Promega) and 2,5 
pmol/µl of Oligo (dT) primers (GenBiotech). cDNAs were then subjected to real time 
quantitative PCR (RT-qPCR) using FastStart SYBR Green Master (04673484001, Roche) 
and 200 nM of each specific primer (Invitrogen, life technologies
TM
):   
 
IL-8: forward 5’-AAGGAAAACTGGGTGCAGAG-3’ and reverse 5’-
GGCATCTTCACTGATTCTTGG-3’ 
FGF-2: forward 5’-CCTGGCTATGAAGGAAGATGG-3’ and reverse 5’-
TCGTTTCAGTGCCACATACC-3’ 
TSG-6: forward 5’-CATATGGCTTGAACGAGCAGC-3’ and reverse 5’- 
CTTTGCGTGTGGGTTGTAGC-3’ 
RHAMM: forward 5’- TGGAAAAGATGGAAGCAAGG-3’ and reverse 5’- 
CCAGTGTAGCATTATTTGCAGAG-3’ 
CD44: forward 5’-GTGATGGCACCCGCTATG-3’ and reverse 5’-
ACTGTCTTCGTCTGGGATGG-3’ 
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GAPDH: forward 5’-GGGGCTGCCCAGAACATCAT-3’ and reverse 5’-
GCCTGCTTCACCACCTTCTTG-3’ 
PCR conditions were: 90 seconds at 94°C and then 40 cycles of 30 seconds at 94°C, 30 




To analyze TSG-6 biosynthesis in MØ supernatants, equal amounts of protein were resolved 
by 0.1% SDS-10% polyacrylamide gel denaturing electrophoresis (SDS-PAGE) and 
transferred to a nitrocellulose membrane. The membranes were incubated overnight at 4°C 
with RAH-1 a polyclonal human TSG-6 antibody[38] (kindly supplied by Dr. Anthony Day) 
and then incubated for 1 hour at RT with horseradish peroxidase-labeled secondary antibody. 
Finally, HRP chemiluminescence reaction was detected using a stable peroxide solution and 
an enhanced luminol solution. Images were obtained with ImageQuant 4000 mini 
bioluminescent image analyzer (GE HealthCare LifeSciences) and analyzed using ImageJ. 
 
Gelatin zymography 
Matrix Metalloproteinases (MMPs) activity in MØ supernatants was determined by gelatin 
zymography [39] . Conditioned media was run on a 10% SDS PAGE containing 0.1% gelatin 
(Sigma-Aldrich). Following electrophoresis, gels were washed with 50 mM Tris-ClH pH 7.5, 
2.5% Triton X-100 30 min, 50 mM Tris-ClH pH 7.5, 2.5% Triton X-100, 5 mM CaCl2, 1 mM 
ZnCl2 30 min and 50 mM Tris-ClH pH 7.5, 2.5% Triton X-100, 10 mM CaCl2, 200 mM NaCl 
48 h at 37°C. The gel was stained with Coomassie Brilliant Blue R-250 for 30 min at room 
temperature. Gelatinase activity was visualized by negative staining; gel images were 
obtained with a biomolecular imager (ImageQuant LAS 4000 mini) and were subjected to 
densitometric analysis using ImageJ 1.50b software package (National Institutes of Health). 
Fold change MMP-2 and MMP-9 activity was obtained by normalizing values to untreated 
samples. 
 
In vitro endothelial cell migration assay 
In vitro migration was performed using a 48-Transwell microchemotaxis Boyden Chamber 
unit (Neuroprobe, Inc.). HMEC-1 (1.5x10
3
 cells/well) were placed in the upper chamber and 
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unit. As a negative control cells were exposed to DMEM and RPMI without FBS and as a 
positive control a medium rich in angiogenic factors was used. The chamber was left for 4 
hours at 37°C in a 5% CO2 humidified atmosphere. Cells attached to the lower side of the 
membrane were fixed in 2% formaldehyde and stained with 4′,6-diamidino-2-phenylindole 
dihydrochloride (DAPI, Sigma-Aldrich). Images from 3 representative visual fields were 
captured using Nikon Eclipse E800 fluorescence microscope and were analyzed using 
CellProfiler software (www.cellprofiler.com), and the mean number of cells/field ± SEM was 
calculated. 
 
Tumor xenograft model 
Six-to-eight-week-old male nu/nu mice were purchased from Comisión Nacional de Energía 
Atómica, Ezeiza, Buenos Aires, Argentina. Animals were maintained at our Animal 
Resources Facilities (CIBA, CIT NOBA) in accordance with the experimental ethical 
committee and with the NIH Guide for the Care and Use of Laboratory Animals (eighth 
edition). MDA-MB-231 or LoVo cell suspension (1x10
7
 cells/0.1 ml) was injected 
subcutaneously in the dorsal flank of mice. After 9 days, PBMCs derived Mo/MØ treated or 
not with LMW or HMW HA were inoculated subcutaneously near the base of the tumor.  On 
day 29 mice were sacrificed and tumors were removed, fixed in 10% formalin and embedded 
in paraffin. Before staining, 3-μm sections were deparaffinized and dehydrated.  
 
Detection of angiogenesis in tumor tissues  
Slides were rinsed with PBS and dye with DAPI 0.3 µg/ml plus fluorescein labeled Griffonia 
(Bandeiraea) Simplicifolia Lectin I 20 µg/ml (GSL I; FL-1101, Vector Laboratories) that 
binds specifically to endothelial cells in mouse tissues [40]. The sections were rinsed with 
PBS and then mounted on microscope slides. Images of the stained sections were taken with 
a Nikon Eclipse E800 fluorescence microscope. Microvessels were quantified with ImageJ. 
  
Immunostaining of TSG-6 and HA in tumor tissues 
Slides were rinsed with PBS and incubated overnight at 4°C with rabbit anti-human 
polyclonal against TSG-6 (RAH-1)[38] and HA binding protein (385911, Calbiochem). 
Afterward, the tissue slices were washed three times in PBS and then incubated for 1 h at 4°C 
with secondary rabbit antibody conjugated with Texas Red® (TI-1000, Vector Laboratories) 
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with PBS, dye with DAPI 0.3 µg/ml and then mounted on microscope slides. Images of the 
stained sections were taken with a Nikon Eclipse E800 fluorescence microscope and 
quantified with ImageJ.  
 
Microarray datasets processing 
Publicly available mice microarray datasets GSE18404 (breast carcinoma) and GSE67953 
(colorectal carcinoma) were used for comparing differential TSG-6 expression levels in 
TAMs and spleen MO. In each dataset, NCBI GEO2R tool ( 




For statistical analysis, 95% confidence intervals (CI) were determined by calculating 
arithmetic mean values and variance (standard deviation, SD) of three independent 
experiments. To evaluate whether differences between the values obtained were significant, 
analysis of variance (ANOVA, Tukey Test) was used to evaluate the differences between 
values of more than two experimental groups. The software Prism (GraphPad, San Diego, 
CA, USA) was used, considering a p value<0.05 as statistically significant. 
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Figure 1. Characterization of Mo/MØ by Flow Cytometry. Mo/MØ culture treatments 
stained with mAbs anti A) HLA, B) CD14, C) CD80 and D) CD206. Mo/MØ were gated and 
the co-expression of the markers were analyzed. Data are expressed as mean percentage ± 
SEM from three independent experiments. Data was analyzed through one‐ way ANOVA 
analysis. BC = basal control; LMW HA = low molecular weight hyaluronan; HMW HA = 
high molecular weight hyaluronan; MTL = MDA-MB-231 tumor cell lysate; LTL = LoVo 
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Figure 2. Cell Viability. Mo/MØ were cultured with A) different concentrations of MTL or 
LTL and B) MCM or LCM, and cell viability was measured using MTS assay. Data are 
expressed as optical density (OD) mean ± SEM from three independent experiments. (***) 
p<0.001 vs. control, one‐ way ANOVA analysis. C - = negative control, cell death was 
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Figure 3. In vitro angiogenesis in Mo/MØ treated with HA. (A and B) VEGF, (C and D) 
IL-8 and (E and F) FGF-2 mRNA expression levels were measured by RT-qPCR in Mo/MØ. 
Data are expressed as normalized relative quantities (NRQ) mean ± SEM, from three 
independent experiments. (*) p<0.05, (**) p<0.01 and (***) p<0.001, one‐ way ANOVA 
analysis. BC = basal control; LMW HA = low molecular weight hyaluronan; HMW HA = 
high molecular weight hyaluronan; MTL = MDA –MB 231 tumor cell lysate; MCM= MDA –
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Figure 4. MMPs activity and mRNA levels in Mo/MØ treated with HA. (A; C; E and G). 
MMPs activity was analyzed by gelatin zymography.  MMP-2 activity in Mo/MØ 
supernatants treated with TL (C) or CM (G) and HA (LWW and HMW).  MMP-9 activity in 
Mo/MØ supernatants treated with TL (A) or CM (E) and HA (LWW and HMW). The 
activity was quantified by densitometry and relative activity was obtained by normalizing 
values to untreated samples. Data are expressed as fold change mean ± SEM and correspond 
to three independent experiments. (B; D; F and H) mRNA expression levels measured by RT-
qPCR. MMP-2 mRNA levels in Mo/MØ supernatants treated with TL (D) or CM (H) and HA 
(LWW and HMW) and MMP-9 mRNA levels in Mo/MØ supernatants treated with TL (B) or 
CM (F) and HA (LWW and HMW) Data are expressed as normalized relative quantities 
(NRQ) mean ± SEM, from three independent experiments.  
(*) p<0.05, (**) p<0.01 and (***) p<0.001, one‐ way ANOVA analysis. BC = basal control; 
LMW HA = low molecular weight hyaluronan; HMW HA = high molecular weight 
hyaluronan; MTL = MDA –MB 231 tumor cell lysate; MCM= MDA –MB 231; conditioned 
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Figure 5. Endothelial cells migration towards Mo/MØ supernatants treated with HA. 
Results are expressed as an index of cell migration with respect to nontreated BC ± SEM 
from three representative visual fields. Results are representative of three independent 
experiments. (*) p<0.05 and (***) p<0.001, one‐ way ANOVA analysis. BC = basal control. 
LMW HA = low molecular weight hyaluronan; HMW HA = high molecular weight 
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Figure 6. HA receptors mRNA levels in Mo/MØ treated with HA. (A-F) CD44, TLR-4, 
RHAMM mRNA expression levels measured by RT-qPCR mRNA levels measured by RT-
qPCR in Mo/MØ treated with TL (A; C and E) or CM (B; D and F) and HA (LWW and 
HMW). Data are expressed as normalized relative quantities (NRQ) mean ± SEM, from four 
independent experiments. (*) p<0.05, (**) p<0.01 and (***) p<0.001, one‐ way ANOVA 
analysis. BC = basal control; LMW HA = low molecular weight hyaluronan; HMW HA = 
high molecular weight hyaluronan; MTL = MDA –MB 231 tumor cell lysate; MCM= MDA 
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Figure 7. In vivo angiogenesis in cancer xenograft model. (A) MDA-MB-231 model and 
(B) LoVo model. H&E: tumors were fixed and stained with hematoxylin/eosin. GSL-1: 
quantification of GSL-1-FITC (binds specifically to endothelial cells) by fluorescence 
microscopy in tumor sections of breast cancer xenograft model. Nude mice were inoculated 
with MDA-MB 231 or LoVo and at day 9 tumors with a similar volume where inoculated 
with MO/MØ previously treated or not with LMW or HMW HA. Tumors were fixed and 
stained with GSL1-FICT (green, endothelial cells) and DAPI (blue, nuclei). Bars represent 
the average of GSL-1-FITC+/field ± SEM from ten representative visual fields. (*) p<0.05, 
(**) p<0.01 and (***) P<0.001, one‐ way ANOVA analysis. TC = Tumor Control; Mo/MØ 
= monocytes/ macrophages; LMW HA = low molecular weight hyaluronan; HMW HA = 
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Figure 8. Microarray datasets GSE18404 (breast carcinoma) and GSE67953 (colorectal 
carcinoma) were used for comparing differential TSG-6 expression levels in TAMs and 











This article is protected by copyright. All rights reserved. 
 
 
Figure 9. TSG-6 mRNA and protein levels in Mo/MØ treated with HA. (A and C) TSG-6 
mRNA expression levels were measured by RT-qPCR in Mo/MØ treated with TL (A) or CM 
(C) and HA (LWW and HMW). Data are expressed as normalized relative quantities (NRQ) 
mean ± SEM, from three independent experiments. (B and D) TSG-6 protein levels were 
measured by western blot in Mo/MØ supernatants MØ treated with TL (B) or CM (D) and 
HA (LWW and HMW). TSG-6‧ HC (~120 kDa) right panel; Free TSG-6 (~35 kDa) left 
panel. Protein levels were quantified by densitometry from four independent experiments. (*) 
p<0.05, (**) p<0.01 and (***) p<0.001, one‐ way ANOVA analysis. BC = basal control; 
LMW HA = low molecular weight hyaluronan; HMW HA = high molecular weight 
hyaluronan; MTL = MDA –MB 231 tumor cell lysate; MCM= MDA –MB 231; conditioned 
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Figure 10. TSG-6 and HA immunostaining in cancer xenograft model. (A) MDA-MB-
231 model, (B) LoVo model. Tumors sections were stained with: TSG6 and anti-rabbit 
conjugated with Texas Red (red, TSG-6); HA binding protein biotinylated and streptavidin-
FITC (green, total HA); and DAPI (blue, nuclei). Bars represent the average of TSG-6+ or 
HA+/field ± SEM from ten representative visual fields. (*) p<0.05, (**) p<0.01 and (***) 
P<0.001, one‐ way ANOVA analysis. TC = Tumor Control; Mo/ MØ = 
monocytes/macrophages; LMW HA = low molecular weight hyaluronan; HMW HA = high 















Figure 11. TSG-6 protein levels in Mo/MØ treated with HA derived from patients 
(breast and colorectal cancer).  (A) TSG-6 protein levels were measured by western blot in 
Mo/MØ supernatants MØ treated with TL derived from breast or colorectal tumor tissue and 
HA (LWW and HMW). (B) TSG-6 protein levels were measured by western blot in Mo/MØ 
supernatants MØ treated with NATL derived from breast or colorectal normal tissue adjacent 
to the tumor. TSG-6‧ HC (~120 kDa) right panel; Free TSG-6 (~35 kDa) left panel. Protein 
levels were quantified by densitometry and expressed as arbitrary units (AU) mean ± SEM, 
from four independent experiments. (*) p<0.05, one‐ way ANOVA analysis. BC = basal 
control; LMW HA = low molecular weight hyaluronan; HMW HA = high molecular weight 
hyaluronan; TTL = tumor tissue lysate; NATL= normal tissue adjacent to the tumor lysate.      
